Skip to Main Content


Latest News

Inhibition of Small RNA in Lung Macrophages May Counter Pulmonary Fibrosis

Researchers at the Yale School of Medicine (YSM) who study idiopathic pulmonary fibrosis, a debilitating and fatal lung disease, designed a molecule that reverses pulmonary fibrosis in a preclinical model of the disease and in cultured human lung tissue. The drug inhibits a microRNA, called miR-33, and protects against fibrosis by improving the metabolic functions of lung macrophages. The results appeared online on January 10, 2023, in JCI Insight.

Read more